- Home
- IMNM
IMNM
Immunome Inc.
as 11-15-2024 4:00pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 747.7M | IPO Year: | 2020 |
| Target Price: | $28.60 | AVG Volume (30 days): | 695.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.93 - $30.96 | Next Earning Date: | 11-13-2024 |
| Revenue: | $10,129,000 | Revenue Growth: | -0.62% |
| Revenue Growth (this year): | -38.89% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunome Inc. (IMNM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rosett Max | IMNM | Chief Financial Officer | Sep 19 '24 | Sell | $16.01 | 14,380 | $230,223.80 | 47,476 |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
4 days ago
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
Business Wire
4 days ago
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
Zacks
5 days ago
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates
MT Newswires
9 days ago
Stephens Starts Immunome With Overweight Rating, $30 Price Target
Business Wire
12 days ago
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
Business Wire
16 days ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
18 days ago
Immunome Advances with Strategic Asset Acquisition and Agreement
Compare IMNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.